Next-Generation-Sequencing for Non-Invasive Prenatal Testing (NGS-NIPT) in China
The Market for Next-Generation-Sequencing Neonatal Testing (NGS-NIPT) in China
The stakes are high for clinical next-generation sequencing (NGS) platform vendors in the Chinese market. Already home to a significant amount of all laboratories worldwide providing clinical genetic testing services, China is playing an increasingly significant role not only in the IVD industry, but in global clinical markets.
This report, Next Generation Sequencing for NIPT in China estimates the market for Non Invasive Prenatal Testing in this emerging market, and generally examines the role of next generation sequencing in the company. The report provides information on approved NGS instruments, Chinese institutions using NGS, companies that offer NIPT services as well as definitive market size and share for this market.
As part of its market analysis this report includes:
Market for Non-Invasive Prenatal Testing using Sequencing in China
Forecast to 2020
Key Equipment Manufactuers and Service Providers
Chinese NGS Company Profiles
Despite slackened economic growth, the country remains a source of tremendous demand for clinical innovation and higher standards of care. Outside of North America, Europe and Japan, China is primed to emerge as the leading market for clinical NGS and molecular cancer testing.
Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).
Please note that your term must be at least three characters long and numbers will be blocked by the # sign.